Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia

Mishari HM Alshyarba¹, Abdulaziz Alamri¹, Alhassan Alamer Assiri²

¹Department of Surgery (Urology Division), College of Medicine, King Khalid University, P.O. Box 641, Abha 61421, Kingdom of Saudi Arabia, ²Urology Resident, King Khalid University Hospital, Abha, Saudi Arabia

Abstract

Objective: To report the magnitude, the financial and the economic impact of Bacillus Calmette-Guérin (BCG) shortage in our institute and transfer of non-muscle invasive bladder cancer (NMIBC) patients to higher centers to receive the treatment. Methods: This is a retrospective study, between January 2015 and December 2017, the cases of NMIBC diagnosed at Aseer Central Hospital, Abha, Saudi Arabia were studied. Demographic features, clinical presentations, histopathological features, and the BCG therapy shortage and its economic impact were addressed. Results: Over a three years study review of 62 urothelial bladder cancer, NMIBC was diagnosed in 55 (89%) patients. Forty-three (78%) patients were males and 12 (22%) patients were females. The mean age ± standard deviation (SD) (range) in this cohort was 59 ± 12 years (38–87). Gross hematuria was the main presentation in 51 (92%) patients of this cohort. Dysuria and other lower urinary tract symptoms were the presentations in 18 (32%) patients. Smoking history was positive in 33 (60%) patients and the rest 22 (40%) patients denied any form of tobacco consumptions. The BCG eligible were 46 (84%) patients of all NMIBC patients in this study. Twenty-seven (59%) patients of them received BCG in our institute. The rest 19 (41%) patients were opted to be transferred to a higher medical center to receive the BCG because of the BCG shortage in our center. The financial cost of traveling to receive the six-weeks induction BCG therapy was on average of 7200 Saudi riyals (1.745 €) for every patient. Conclusions: The BCG shortage in our institute is almost approaching half of eligible BCG cases. This has had an economic impact on the health budget. Such health catastrophe could be mitigated with proper health plans of a provision of the BCG to all tertiary care centers. Alternative therapies for such cases should be considered in cases of global BCG shortage.

Keywords: Bacillus Calmette-Guerin, cost-effectiveness, intravesical, non-muscle-invasive bladder carcinoma

Introduction

Bladder cancer is the 7th most common cancer in men and the 17th most common cancer in women worldwide with an age-standardized incidence of 17 and 6/100,000, respectively.[¹] More than 70% of all bladder cancers are non-muscle invasive bladder cancer (NMIBC). Mortality of bladder cancer has decreased reflecting an advancing development of new therapeutic approaches.[²,³]

Transurethral resection of the bladder tumor (TURBT) followed by an adjuvant intravesical instillation with Bacillus Calmette-Guérin (BCG) is the most effective conservative therapy for the treatment of high-risk NMIBC.[⁴,⁵] It can...
significantly reduce the probability of both disease recurrence and progression, thereby potentially improving survival.\[3,9\]

In July 2012, Sanofi Pasteur (Lyon, France) announced that it was halting the production of ImmuCyst, the Connaught strain of BCG, after inspectors found mold in the sterile manufacturing area of Toronto, Canada, following a flood.\[8\] The Toronto facility was the only one in the world manufacturing ImmuCyst, the market leader in many countries including the United Kingdom and the United States. This halt led to a severe worldwide shortage of BCG as other manufacturers struggled to keep up with demand.

Adding to the worldwide BCG shortage, there is considerable cost variation across countries. This was related to differences in practices such as inpatient or outpatient care, duration of hospitalization, methods of calculating costs and billing, cancer incidence, and the type and intensity of treatment and testing. Another source of variation in the cost of care is the method of estimating economic efficiency. In some European countries, BCG 6-week induction course varies from 528–975 €.\[10\]

This worldwide BCG shortage was clearly manifested in Saudi Arabia. It was more predominant in peripheral Saudi provinces. For such reasons, patients were referred to higher national centers to receive BCG therapy.

The objective of this study is to measure the incidence of NMIBC patients treated in our institute over three years. Second to estimate the financial cost and the economic impact of receiving BCG in higher centers. This is the first study from Saudi Arabia to address and enlighten on this financial concern.

**Materials and Methods**

This research was approved on March 16, 2017 by the Research Ethics Committee (REC# 2017-2-8) of the College of Medicine, King Khalid University, Abha, Saudi Arabia. We scrutinized the cases of urothelial bladder cancers diagnosed at Aseer Central Hospital, Abha, Saudi Arabia between January 2015 and December 2017. The NMIBC incidence, demographic, clinical presentations, and pathological features were evaluated.

Based on the BCG therapy indication, we divided NMIBC patients into either BCG eligible or BCG non-eligible patients. BCG eligible are patients with high-risk NMIBC (high-grade Ta, or any grade T1 or carcinoma in situ (CIS)). Patients with low-risk NMIBC (i.e. those that are small, solitary and presenting for the first time) are not eligible for BCG therapy. Intravesical BCG therapy was given as induction therapy two weeks after transurethral resection of bladder tumor (TURBT) on weekly intravesical therapy for six weeks. Then, maintenance intravesical therapy monthly for six months. Regular check cystoscopy for local recurrence or progression of the bladder cancer is done every three months in the first two years.

We defined BCG shortage if a patient was diagnosed with NMIBC and was a BCG eligible, but BCG was not commenced 4 weeks after TURBT due to the non-availability.

The financial cost of transfer to higher centers was estimated using a designed model including the flight cost, housing accommodation cost, and the daily budget for transportation and meals. This cost was just estimated for the BCG induction therapy only. The BCG shortage solutions were concisely reviewed.

**Statistical analysis**

The incidence of NMIBC cases in our institute was measured. The economic impact and the financial cost of transferring patients to a higher center to receive the BCG therapy were estimated. Statistical Package for Social Sciences (SPSS) software was used for the analysis.

**Results**

Over three years review, 62 cases of urothelial cancers were diagnosed at our health center. NMIBC was in 55 (89%) patients. Forty-three (78%) patients were males and 12 (22%) patients were females. The mean age ± SD (range) in this cohort was 59 ± 12 years (38–87). Gross hematuria was the main presentation in 51 (92%) patients. Dysuria and other lower urinary tract symptoms were observed in 18 (32%) patients of the study cohort. Smoking history was positive in 33 (60%) patients. A chronic indwelling catheter was used in 15 (27%) patients. Eight (14%) patients showed a history of urinary bilharziasis [Table 1].

The histologic grading of the NMIBC specimens was as the following. Most of our study series were predominantly T1 in 34 (62%) patients. Ta, however, was in 9 (16%) patients. Tis in 12 (22%) patients of this study [Table 1].

The BCG eligible were 46 (84%) patients of all NMIBC patients in this study. Twenty-seven (59%) patients received BCG in our institute. The rest 19 (41%) patients were opted to be transferred to a higher medical center to receive the BCG because of the BCG shortage in our center [Table 1].

The financial cost of traveling to receive the six weeks induction BCG therapy was in 7200 Saudi riyals (1.745 €) on an average for every single patient [Table 2].

**Discussion**

BCG immunotherapy is a live-attenuated strain of *Mycobacterium bovis* that is indicated in intermediate and high-risk T1, high grade or carcinoma in situ (CIS) of NMIBC after transurethral resection (TUR).\[11\] High-risk NMIBC represents a challenging disease state with up to 80% and 45% of patients experiencing disease recurrence and progression at 5 years, respectively.\[11\]

In our series, 89% of the urothelial bladder cancer cases were NMIBC. This slightly elevated the rate than those reported in
the literature[1,2] is perhaps related to the early presentation of our patients because of the free and quick access to the health facilities.

The 6-week induction schedule of BCG is still administered as described originally by Morales et al.[3] In our institute, we are following these recommendations. However, the ideal maintenance schedule is less clear.[4] The most commonly utilized maintenance schedule is 3-weekly instillations at months 3, 6, and 12, and beyond up to 3 years.[3]

A total of 41% of our BCG eligible patients were referred to higher health services because of the BCG shortage in our institute. For the induction BCG therapy only, the approximate financial cost was 7200 Saudi riyals (1.745 €) on average per patient. This obviously has an economic impact on the health budget. The social and psychological impact of sending patients to higher centers for the BCG need to be addressed by future studies.

The BCG shortage has various clinical implications at different levels. First, the shortage of the vaccine may force physicians to lower the administered BCG dose or shift to less efficacious treatment options with potential implications on disease outcomes. Second, BCG shortage may lead to a reduction in maintenance courses resulting in, a possible, suboptimal treatment.[4,5] It is not currently known whether such a reduction, for example, four instead of six instillations during induction and two instead of four during maintenance, is sufficient. Moreover, the increased price of the only other available therapeutic options such as intravesical chemotherapy will increase the burden on patients as well as on health-care systems.[6,7]

In the absence of sufficient BCG supply, mitomycin c (MMC) represents an appealing alternative to BCG when considering progression as the most important endpoint because results from individual patient data meta-analysis did not find a statistically significant difference between BCG and MMC in term of progression, cancer-specific or overall survival.[8,9] After MMC induction, a maintenance course should be administered. The optimal maintenance is not clear yet. Nevertheless, the maintenance schedule for more than 1 year is generally not recommended.[10] It should be stressed that intravesical MMC has a higher risk of recurrence but a lower risk of side-effects.

Device-assisted intravesical chemotherapy instillations such as microwave-induced hyperthermia and electromotive drug administration hold the promise to improve patient outcomes. The utilization of hyperthermia with local chemotherapeutics is reported to provide a synergistic effect for decreasing the proliferation of urothelial carcinoma.[11] Data on patients treated with intravesical thermo-chemotherapy (hyperthermia and MMC) especially using Synergo radiofrequency-induced hyperthermia (Amstelveen, The Netherlands) showed low rates of recurrence and higher bladder preservation in comparison with MMC alone.[12-15]

Intravesical gemcitabine, an antimetabolite could also be a reasonable alternative when BCG is not available.[20,21] In fact, gemcitabine showed similar efficacy to BCG in intermediate-risk NMIBC and higher efficacy in BCG-refractory patients with a lower toxicity profile.[22,23] Similarly, gemcitabine demonstrated higher efficacy and lower toxicity in comparison with MMC in patients with recurrent NMIBC as well as refractory NMIBC.[24] Unfortunately, it was less effective than BCG in patients with high-risk NMIBC.[25]

High-risk NMIBC (e.g. pT1HG/G3 ± CIS) represents a very challenging disease state. Despite adequate treatment with TUR and BCG, about 20% of patients experience disease progression to muscle-invasive bladder cancer. Radical cystectomy provides excellent oncological outcomes. However, up to 50% of patients will be overtreated if all high-risk patients undergo radical cystectomy.[26] The proper selection of the optimal candidate for immediate radical cystectomy without overtreating patients likely to respond to BCG is the real dilemma.

The current status of BCG shortage should trigger an alarm to evaluate every possible therapeutic pathway to provide sufficient patient care. Responsible medical authorities should be encouraged to support domestic BCG production to provide optimal care for patients with NMIBC. The potential reduction in competition among manufacturers could result in more frequent and long-term drug shortages and an increase in the price of products. Accordingly, establishing nonprofit manufacturers
could improve competition and address generic drug market failure and supply market demand steadily.\cite{27}

It is the first study from Saudi Arabia to address this BCG shortage of economic impact on patients. Since it was a retrospective review and a quite short number of cases, this, however, debilitates its power. Large prospective comparative studies are warranted. Furthermore, the social and psychological impacts of BCG shortages on patients need to be deeply evaluated.

**Conclusion**

The BCG shortage in our institute has had an economic impact on the health budget. Such health catastrophe could be mitigated with proper health plans on the provision of the BCG to all tertiary care centers. Alternative therapies for such cases should be considered in cases of global BCG shortage. Domestic BCG manufacturing should be the optimal goal of health policy planners to encounter the BCG shortage and its health and economic consequences. Until the problem of BCG shortage is addressed, more efforts should be undertaken to identify predictive biomarkers to select the potential patients who are likely to respond to BCG immunotherapy.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/. [Last accessed on 2016 Mar 16].
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013;64:639-53.
3. Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11-9.
4. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2017;71:447-61.
5. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
6. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16.
7. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
8. Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, et al. Adjuvant intravesical bacillus Calmette-Guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92-8.
9. Mould at Toronto plant may affect supplies of cancer drug. Canadian Press Web site. Available from: http://www.cbc.ca/news/canada/toronto/mould-at-toronto-plant-may-ffect-supplies-of-cancer-drug.1.1282152. [Last accessed on 2014 Nov 04].
10. Svatek RS, Hollenbeck BK, Holmâng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur Urol 2014;66:253-62.
11. Rieken M, Shariat SF, Kluth L, Crivelli JJ, Abufaraj M, Foerster B, et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol Semin Orig Invest 2018;36:8.e17-24.
12. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
13. Davies BJ, Hwang TJ, Kesselheim AS. Ensuring access to injectable generic drugs: The case of intravesical BCG for bladder cancer. N Engl J Med 2017;376:1401-3.
14. Messing EM. The BCG shortage. Bladder Cancer 2017;3:227-8.
15. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Guérin in inter- mediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One- third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-72.
16. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-19.
17. Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij J, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high- risk non-muscle-invasive bladder cancer. Eur Urol 2016;69:1046-52.
18. Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270-6.
19. Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Lafer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81-93.
20. Prasanna T, Craft P, Balasingam G, Haxhimolla H, Pranavan G. Intravesical gemcitabine versus intravesical
Bacillus Calmette-Guerin for the treatment of non-muscle invasive bladder cancer: An evaluation of efficacy and toxicity. Front Oncol 2017;7:260.

21. Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG. Intravesical gemcitabine therapy for nonmuscle invasive bladder cancer (NMIBC): A systematic review. BJU Int 2012;109:496-505.

22. Di Lorenzo G, Perdonà S, Damiano R, Faiella A, Cantiello F, Pignata S, et al. Gemcitabine versus Bacille Calmette-Guérin after initial Bacille Calmette-Guérin failure in nonmuscle invasive bladder cancer. Cancer 2010;116:1893-900.

23. Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for nonmuscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294.

24. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mytomycin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. J Clin Oncol 2010;28:543-8.

25. Porena M, Del Zingaro M, Lazzeri M, Meirini L, Giannantoni A, Bini V, et al. Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomised prospective study. Urol Int 2010;84:23-7.

26. D’Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, et al. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. Urol Oncol 2018;36:239.e1-7.

27. Liljenquist D, Bai G, Anderson GF. Addressing generic-drug market failures: The case for establishing a nonprofit manufacturer. N Engl J Med 2018;378:1857-9.